NIH Drops Super-Vaccines: 100% Mouse Protection Against Malaria!
Published Date: 3/9/2026
Notice
Summary
The National Institutes of Health is offering new malaria vaccine inventions for companies to license and develop. These cool nanoparticle platforms show promise in making vaccines super effective, with early tests in mice showing 100% protection. If you’re a business or researcher ready to jump in, now’s the time to connect and start working with these government-owned inventions!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
NIH Offers Malaria Vaccine Tech For Licensing
The National Institute of Allergy and Infectious Diseases (NIAID/NIH) is offering three engineered nanoparticle vaccine platforms for licensing and commercial development under 35 U.S.C. 209 and 37 CFR part 404. The platforms include a PLP synthase nanoparticle displaying 48 copies of up to 4 proteins, a Cpn60 nanoparticle displaying 28 copies of up to 2 proteins, and a Clp nanoparticle displaying 28 copies of up to 2 proteins. To get unpublished information or pursue a license, contact Chris Kornak (240-565-2632, [email protected]) and a signed Confidential Disclosure Agreement is required; reference HHS Ref. No. E-182-2024-0.
Patent Filings Cover Technology
The technology is covered by patent filings: U.S. Provisional Patent Application No. 63/695,288 filed on September 16, 2024, and PCT Patent Application No. PCT/US2025/046419 filed on September 15, 2025. The notice says foreign patent applications have been filed on selected inventions to extend market coverage and those patent rights may be available for licensing.
Pre-Clinical Data Shows 100% Protection In Mice
Pre-clinical data reported in the notice show that nanoparticles displaying the malaria circumsporozoite protein (CSP) conferred 100% sterilizing immunity in mice, and the work is described as being at the pre-clinical developmental stage. The publication cited is: Shi D, et al., Nat Microbiol. 2026;11(1):67-80, doi:10.1038/s41564-025-02209-y.
Opportunity For Collaborative Research
NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these malaria vaccine nanoparticle technologies. Interested parties should contact Chris Kornak at 240-565-2632 or [email protected] to express interest.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2026-04530, Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Basic Requirements for Special Exception Permits and Authorizations To Take, Import, and Export Marine Mammals, Threatened and Endangered Species, and for Maintaining a Captive Marine Mammal Inventory Under Section 104 of the Marine Mammal Protection Act, the Fur Seal Act, and/or Section 10(a)(1)(A) of the Endangered Species Act
NOAA is asking for public feedback on updating the paperwork rules for permits involving marine mammals and endangered species. This affects researchers, businesses, and organizations that take, import, export, or keep these animals. Comments are open until May 8, 2026, helping keep the process clear and efficient without adding extra costs or delays.
Next: 2026-04535, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; HRSA Ryan White HIV/AIDS Program Part F National AIDS Education and Training Center Program Activities, OMB No. 0906-XXXX-New
HRSA is asking for public feedback on a new info collection about the Ryan White HIV/AIDS Program’s training centers. These centers help healthcare workers learn how to better prevent and treat HIV with updated education and support. Comments are open until April 8, 2026, and this review helps keep the program effective without adding extra paperwork or costs.